anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Post-COVID-19 condition (post COVID, also known as long COVID) is a global public health issue estimated to affect over 100 million people. Common symptoms include fatigue, dyspnoea and cognitive dysfunction ('brain fog'). Over time, these symptoms have an adverse effect on mental health, physical activity and quality of life (QoL). The condition requires innovative and feasible treatment approaches that can be effective and self-managed. Physical activity is essential for good health; however, aerobic exercise or weightlifting may not be suitable for post COVID patients who experience fatigue or breathlessness. The benefits of yoga include improved flexibility, mobility, body strength and balance. It is also shown to reduce symptoms of fatigue and improve breathing efficiency, mental health and QoL. This study protocol describes the rationale and methods for a randomised controlled trial (RCT) of a yoga-based intervention designed for adults with post COVID.
METHODS AND ANALYSIS: A two-group, parallel, RCT with blinded follow-up assessments. Participants will be randomised with a 1:1 allocation to either a 12-week yoga-based intervention or a 12-week health promotion (active comparison) intervention. In total, 88 participants aged 30-65 years will be recruited and randomised. The primary outcome is health-related QoL (36-item Short-Form). Secondary outcomes are dyspnoea, fatigue, sleep quality, cognitive functions, mental fatigue, depression, anxiety, physical activity, demographic data and physical health measures. Data will be analysed as intention-to-treat basis, using linear mixed modelling. All assessments are conducted at Karolinska Institutet in Stockholm, Sweden. The yoga-based intervention will take place at a yoga studio centrally located in Stockholm city.
ETHICS AND DISSEMINATION: The study is approved by the Swedish Ethical Review Authority, reference number 2023/06518-01. All participants must sign written informed consent before enrolment and are free to withdraw from the study at any point. Key results will be available through research articles and seminars.
TRIAL REGISTRATION NUMBER: German Clinical Trials Register, DRKS00032837.
BACKGROUND: Hepatic fibrosis (HF) is a common result of the repair process of various chronic liver diseases. Hepatic stellate cells (HSCs) activation is the central link in the occurrence of HF.
METHODS: ELISA and histological analysis were performed to detect the pathological changes of liver tissues. In vitro, HSCs were treated with TGF-β1 as HF cell model. Combination of GATA-binding protein 3 (GATA3) and miR-370 gene promoter was ensured by ChIP and luciferase reporter assay. Autophagy was monitored by observing the GFP-LC3 puncta formation. The interaction between miR-370 and high mobility group box 1 protein (HMGB1) was verified by luciferase reporter assay.
RESULTS: CCl4-induced HF mice exhibited an increase of ALT and AST, and severe damage and fibrosis of liver tissues. GATA3 and HMGB1 were up-regulated, and miR-370 was down-regulated in CCl4-induced HF mice and activated HSCs. GATA3 enhanced expression of the autophagy-related proteins and activation markers in the activated HSCs. Inhibition of autophagy partly reversed GATA3-induced activation of HSCs and the promotion of GATA3 to hepatic fibrosis. Moreover, GATA3 suppressed miR-370 expression via binding with its promotor, and enhanced HMGB1 expression in HSCs. Increasing of miR-370 inhibited HMGB1 expression by directly targeting its mRNA 3'-UTR. The promotion of GATA3 to TGF-β1-induced HSCs autophagy and activation was abrogated by miR-370 up-regulation or HMGB1 knockdown.
CONCLUSIONS: This work demonstrates that GATA3 promotes autophagy and activation of HSCs by regulating miR-370/HMGB1 signaling pathway, which contributes to accelerate HF. Thus, this work suggests that GATA3 may be a potential target for prevention and treatment of HF.
Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment. Patients also undergo bone marrow biopsy and aspiration and blood sample collection during screening and on the trial.
PURPOSE:To produce a detergent compsn. having low skin stimulation and high detergency and lather booster activity, by incorporating a small amt. of a basic amino acid salt of a particular fatty acid in a soap comprising sodium or potassium salt of a particular fatty acid. CONSTITUTION:In the title detergent compsn., a basic amino acid salt of a 14-22C fatty acid is incorporated in a soap comprising sodium or potassium salt of a 14-22C fatty acid in an amt. of 0.5-15wt.%. Examples of the basic amino acid include lysine, ornithine and arginine.
Opioids regulate various physiological and pathophysiological functions, including cell proliferation, immune function, obesity, and neurodegenerative disorders. They have been used for centuries as a treatment for severe pain, binding to opioid receptors a specific G protein-coupled receptor. Common opioids, like β-endorphin, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO), and dynorphins, have analgesic effects. The use of a potent antagonist, like naltrexone hydrochloride, to block the effects of mu Opioid Receptor (μOR) may result in the withdrawal of physiological effects and could potentially impact immune responses in many diseases including respiratory disease. Asthma is a respiratory disease characterized by airway hyperresponsiveness, inflammation, bronchoconstriction, chest tightness, stress generation and release of various cytokines. Airway inflammation leads recruitment and activation of immune cells releasing mediators, including opioids, which may modulate inflammatory response by binding to their respective receptors. The study aims to explore the role of μOR antagonist (naltrexone) in regulating asthma pathophysiology, as the regulation of immune and inflammatory responses in asthma remains unclear. Balb/c mice were sensitized intranasally by 1% TDI and challenged with 2.5% TDI. Naltrexone hydrochloride (1 mg/kg body weight) was administered through intraperitoneal route 1 h before TDI induction. Blocking μOR by naltrexone exacerbates airway inflammation by recruiting inflammatory cells (lymphocytes and neutrophils), enhancing intracellular Reactive oxygen species in bronchoalveolar lavage fluid (BALF), and inflammatory mediator (histamine, Eosinophil peroxidase and neutrophil elastase) in lungs. Naltrexone administration modulated inflammatory cytokines (TNF-α, IL-4, IL-5, IL-6, IL-10, and IL-17A), and enhanced IgE and CRP levels. Naltrexone administration also increased the expression of NF-κB, and phosphorylated p-P38, p-Erk, p-JNK and NF-κB by inhibiting the μOR. Docking study revealed good binding affinity of naltrexone with μOR compared to δ and κ receptors. In future it might elucidate potential therapeutic against many respiratory pathological disorders. In conclusion, μOR blocking by naltrexone regulates and implicates inflammation, bronchoconstriction, and lung physiology.
Patients randomized to minocycline will receive 200mg administered once a day for 21 days. The first dose will be administered in the emergency room or the angiography suite prior to endovascular intervention or within the first two hours of endovascular stroke intervention. If the patient is considered able to swallow as per the routine swallow test, the study drug will be administered orally as intact capsules. If the patient is considered to be at any risk for aspiration or is unable to swallow based on swallowing evaluation, study drug may be started using intravenous route and later switched to oral or via feeding tube as it becomes available.
PURPOSE:To provide a skin-cleaning and wiping agent composition softening the surface of toilet paper, reducing the abrasion of the paper with skins, and giving an excellent wiping and protecting effect. CONSTITUTION:A polysaccharide obtained from tuberose is dissolved in an aqueous solvent such as a monohydric lover alcohol, a dihydric lower alcohol (e.g. polyethylene glycol or propylene glycol) or polyhydric alcohol (e.g. glycerol) to prepare a skin-cleaning and wiping agent composition. The composition as a raw solution is preferably charged in an aerosol container to produce an aerosol preparation, or the composition is preferably charged in a pump style spray container to produce a spraying preparation. The aerosol preparation or the spraying preparation is directly sprayed to the skins of anus peripheral parts, urinary organ peripheral parts or pudendum peripheral parts, etc., or sprayed or coated on toilet paper, etc. The polysaccharide is preferably obtained the tissue culture of tuberose and compounded in a dry solid amount of 0.001-10wt.%, preferably 0.01-5wt.%.
Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate.

Nitrous oxide decreases the MAC of isoflurane (see DOSAGE AND ADMINISTRATION). 

Isoflurane potentiates the muscle relaxant effect of all muscle relaxants and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of isoflurane at equilibrium reduce the ED95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N2O/opioid anesthesia. If added relaxation is required, supplemental doses of muscle relaxants may be used.

Isoflurane is similar to sevoflurane in the sensitization of the myocardium to arrhythmogenic effect of exogenously administered adrenaline. Doses of adrenaline greater than 5mcg/kg, when administered submucosally may produce multiple ventricular arrhythmias. Isoflurane may lead to marked hypotension in patients treated with calcium antagonists.

Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects.

Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures.
The present invention relates to edible gelatin accompanying water, which can be used as a drug administration aid in the medical or food industrial field. The edible gelatin is used to allow anyone to take a medicine easily and comfortably with no repulsion depending on materials used for outer shells. Such edible gelatin is an easily available and economical material used widely for medicines without causing any problem. The edible gelatin as a drug administration aid includes: an outer shell material including edible gelatin (primarily animal gelatin, but the other materials may be considered to meet globalization of the product); an inner core material filled with drinkable water; and a guide of expiration date attached for the safety of users. The edible gelatin has a size suitable for drinking and easy swallowing, is provided in a hexahedron-like shape with a width and a length of about 2 cm x 2 cm, and includes an inlet having a variable size suitable for receiving a pill or a capsule, such as a length of 0.5 cm. The edible gelatin makes it easy to take a solid drug hard to be administered to aged or young patients, and is useful in the outdoor environment, such as a distress or emergency situation, hard to get edible drinking water. In addition, the edible gelatin can be used as a substitute for edible water for drinking in an urgent situation even without any drug.
A method of selectively recovering a hydrophobic target substance. The method is applied to a solution of the target substance in a hydrophobic solvent. An insoluble polysaccharide is combined with the solution, the solution is passed over the insoluble polysaccharide or otherwise exposed to the insoluble polysaccharide. A hydrophilic solvent, which is less hydrophobic than the hydrophobic solvent, is combined with the solution or combined with the hydrophobic target substance and the insoluble polysaccharide after evaporation of the hydrophobic solvent to facilitate binding of the insoluble polysaccharide with the target substance rather than remaining in solution in the hydrophobic solvent. The cyclic polysaccharide is isolated from the solution. A dissociation solvent is combined with the cyclic polysaccharide for solubilizing the target substance from the cyclic polysaccharide and recovering the target substance.
Doxycycline injections improve the appearance of cosmetically significant lower eyelid festoons and malar edema, as well as of the jowls. The doxycycline is also useful for reducing edema of turbinates, the nasal concha or conchae shell-shaped networks of bones, vessels, and tissue within the nasal passageways that are responsible for warming, humidifying, and filtering the air as it is inhaled. The doxycline, in a concentration preferably of greater than 10 to 20 mg/ml, preferably in combination with a local anesthetic and optionally with a vasoconstrictor such as epinephrine and a pH buffering agent, is injected into the subcuticular space at the site of swelling. The high viscosity limits the spread of the doxycycline to the area to be treated. The resulting sclerosis prevents fluid accumulation. The doxycline also decreases swelling due to fat, by causing a decrease in lipomas.
BRCA1 mutations substantially elevate the risks of breast and ovarian cancer. Various modifiers, including environmental factors, can influence cancer risk. Lead, a known carcinogen, has been associated with various cancers, but its impact on BRCA1 carriers remains unexplored. A cohort of 989 BRCA1 mutation carriers underwent genetic testing at the Pomeranian Medical University, Poland. Blood lead levels were measured using inductively coupled plasma mass spectrometry. Each subject was assigned to a category based on their tertile of blood lead. Cox regression analysis was used to assess cancer risk associations. Elevated blood lead levels (>13.6 μg/L) were associated with an increased risk of ovarian cancer (univariable: HR = 3.33; 95% CI: 1.23-9.00; p = 0.02; multivariable: HR = 2.10; 95% CI: 0.73-6.01; p = 0.17). No significant correlation was found with breast cancer risk. High blood lead levels are associated with increased risk of ovarian cancer in BRCA1 carriers, suggesting priority for preventive salpingo-oophorectomy. Potential risk reduction strategies include detoxification. Validation in diverse populations and exploration of detoxification methods for lowering lead levels are required.
The members of the Flaviviridae family are becoming an emerging threat for public health, causing an increasing number of infections each year and requiring effective treatment. The consequences of these infections can be severe and include liver inflammation with subsequent carcinogenesis, endothelial damage with hemorrhage, neuroinflammation, and, in some cases, death. The mechanisms of Flaviviridae pathogenesis are being actively investigated, but there are still many gaps in their understanding. Extracellular vesicles may play important roles in these mechanisms, and, therefore, this topic deserves detailed research. Recent data have revealed the involvement of extracellular vesicles in steps of Flaviviridae pathogenesis such as transmission, immune evasion, and inflammation, which is critical for disease establishment. This review covers recent papers on the roles of extracellular vesicles in the pathogenesis of Flaviviridae and includes examples of clinical applications of the accumulated data.
Investigators will recruit families and patients diagnosed with a Cancer Predisposition Syndrome within 3 years. Participants will be provided with a digital care plan and optional accompanying text message reminders.
In-person music therapy session. The music therapist will continue to coach throughout the 30-minute session. Flow Mediated dilation (FMD) and EndoPAT will be measured before and after singing.
PURPOSE: A composition containing syringaresinol for treating eye diseases is provided to normalize the function of mitochondria and to prevent or treat eye diseases especially age-related eye diseases. CONSTITUTION: A composition for preventing or treating eye diseases contains 1-80 wt% of syringaresinol. The eye diseases are selected from the group consisting of macular degeneration, uveitis, glaucoma, diabetic retinopathy, and cataract. Syringaresinol is contained in extracts prepared using one or more selected among linseed, Phellodendron amurense Ruprecht, Acanthopanax senticosus, sesame seeds, and ginseng fruits. The composition enhances SIRT 1 expression and mitochondria synthesis. [Reference numerals] (AA) SIRT1 protein expression
Pain is a common and serious problem after cardiovascular surgery. It is associated with increased morbidity and mortality, and additional risk factors of cardiac surgery such as sternotomy and cardiopulmonary bypass contribute to this. Patient-controlled analgesia with intravenous opioids is standard in many centers for the management of pain after cardiac surgery. However, intravenous opioids have a higher risk of nausea and vomiting and may delay weaning from mechanical ventilation compared to regional techniques. Elderly patients have a higher risk of opioid-related complications, and regional techniques can help reduce postoperative ventilation time and accelerate postoperative recovery, which will reduce the risk of atelectasis, especially in the elderly population. Thoracic paravertebral block (TPVB) is difficult to apply due to its anatomical proximity to important structures such as the pleura and central neuraxial system, and may cause complications such as pneumothorax and vascular injury. Analgesia management is very important in these patients, since insufficient analgesia may cause pulmonary complications such as atelectasis, pneumonia, and increased oxygen consumption in the postoperative period.

Erector spina plane (ESP) block performed with ultrasound (US) is a new interfacial plane block defined by Forero et al. in 2016. If the ESP block is applied at the T5 level, it provides thoracic analgesia, if it is applied at the T7-9 level, it provides analgesia in the abdominal region. This block is applied by injecting a solution containing local anesthetic into the fascia under the erector spina muscle. Since the application site of the ESP block is far from the pleura and neuraxial tissues, it minimizes the risk of complications due to injury to these structures. Sonoanatomy is easy to visualize on US and the spread of local anesthetic can be seen easily. With the cephalo-caudal spread of the local anesthetic solution, analgesia occurs in several dermatomes. Cadaveric studies have shown that the injection spreads to the ventral and dorsal roots of the spinal nerves and creates sensory blockade in both the anterolateral thorax and the posterior. In the literature, it has been reported that it provides effective analgesia in randomized controlled studies investigating the effectiveness of ESP block for postoperative analgesia management after open heart surgery, breast surgery and ventral hernia repair.

In this study, it is aimed to compare the effectiveness of US-guided ESP block and TPVB for postoperative analgesia management after cardiovascular surgery. Our primary aim is to compare postoperative pain scores (NRS), and our secondary aim is to evaluate rescue analgesia using, opioid-related side effects (allergic reaction, nausea, vomiting) and complications that may occur due to block (pneumothorax, hematoma).
FIELD: chemistry.SUBSTANCE: described is a method for reducing concentration of a solvent in a plurality of biodegradable microparticles. Method involves contacting a mixture containing a plurality of microparticles and a solvent with water to form an aqueous suspension. First portion of the solvent is dissolved in water of the aqueous suspension while reducing the concentration of the solvent in the plurality of microparticles from the first concentration of the solvent in the mixture to the second concentration of the solvent in the aqueous suspension. Further, the aqueous suspension is transferred into a concentration device which further reduces the concentration of the solvent from the second solvent concentration to the third solvent concentration. Then, concentrate of microparticles with third concentration of solvent is transferred to flushing device to form amalgam of washed microparticles with fourth concentration of solvent with subsequent drying of amalgam of washed microparticles. Biodegradable microparticles of the invention contain poly(lacto-co-glycol) acid, the solvent in the biodegradable microparticles contains a halogenated organic solvent, preferably methylene chloride. Described also is a system for reducing concentration of a solvent in a plurality of biodegradable microparticles. Microparticles according to the invention can contain a therapeutically active agent, preferably pegylated insulin.EFFECT: disclosed method reduces concentration of solvent in multiple biodegradable microparticles to 0_03 % by weight or less.42 cl, 4 dwg
Efficacy of Benzphetamine Hydrochloride Tablets in combination with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems.

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. Benzphetamine Hydrochloride Tablets should not be used concomitantly with other CNS stimulants.

Amphetamines may decrease the hypotensive effect of antihypertensives. Amphetamines may enhance the effects of tricyclic antidepressants.

Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines. Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
Carcinogenesis 

Carcinogenicity studies were conducted in Wistar Han rats and CD1 mice. Hepatocellular adenomas and carcinomas occurred in male rats at ≥ 10 mg/kg and in females at 30 mg/kg (18- and 65-times the 30 mg twice daily maximum clinical dose, by AUC, respectively). Thyroid follicular adenoma/carcinoma was also observed in male rats at 30 mg/kg. Hepatocellular adenomas and carcinomas occurred in male mice at ≥ 10 mg kg (6 times the maximum clinical dose, by AUC) but not in female mice at any dose ≤ 30 mg/kg (31 times the maximum clinical dose, by AUC). These findings are likely rodent specific and considered not relevant to humans. Genetic profiling studies support activation of hepatic constitutive androstane receptors as the likely tumorigenic mechanism in rodents and is not a significant concern for human risk at clinical exposure to osilodrostat. 

Genotoxicity 

Genotoxicity assays conducted in vitro in bacterial systems and in vitro and in vivo in mammalian systems with and without metabolic activation indicate that there is no genotoxic risk in humans with osilodrostat. 

Impairment of Fertility 

In a fertility and early embryonic-development study in Wistar Han rats, doses of 50 mg/kg (118 times the 30 mg twice daily maximum clinical dose, by AUC) resulted in changes to estrous cyclicity and impaired female fertility and embryo viability. No effect on reproductive performance in females was observed at 5 mg/kg (8 times the maximum clinical dose). Fertility and reproductive performance were not affected in male rats up to 50 mg/kg (77 times the maximum clinical dose, by AUC).
PDT involves cervical gel application and 25-minute laser light exposure. The procedure is repeated three times.